Savara Inc.

Savara Inc.

SVRA·NASDAQ

$5.25

+1.9%
HealthcareBiotechnology

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

At a Glance

Live Snapshot
Market Cap$1.08B
EPS-0.5300
P/E Ratio-9.91
Earnings Date08/06/2026

svra

Gross Profit

Last Annual Value

-245.00K

3-Year CAGR

79%

5-Year CAGR

63%

10-Year CAGR

-5%

Savara Inc.

Savara Inc. Competitors Analysis of Gross Profit

SVRA · NASDAQ
CompanyGross Profit
CAGR 3Y
CAGR 5Y
CAGR 10Y
SVRA logo
Savara Inc.
NASDAQ:SVRA
-245.00K
N/AN/AN/A 
67.42M
N/AN/AN/A
179.14M
810.9%164.1%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
0.00
N/AN/AN/A
0.00
N/AN/AN/A
60.10M
18.1%10.2%N/A
-546.00K
N/AN/AN/A
29.30M
-10.9%0.4%43.3%
PROK logo
ProKidney Corp.
NASDAQ:PROK
-4.83M
N/AN/AN/A
Savara Inc.

Savara Inc. Fair Value Envelope

SVRA · NASDAQ

Our analysis suggests that SVRA has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $5.25, this represents a potential HIDDEN relative to our calculated worth for Savara Inc..

Intrinsic Value
Current Price: $5.25